Key facts
Financial results (Full-year 2021)
Product Sales
Changes at constant exchange rates
Core Earnings per Share
Changes at constant exchange rates
Full-year and Q4 2021 results
10 February 2022
SEC filings
SEC filings are those documents that we are required to file by virtue of our listing on Nasdaq. They contain mainly financial information.
These documents are also available for viewing on the SEC website at www.sec.gov. The Company will send any holder of the Company’s securities, upon request, a hard copy of the Company’s complete audited financial statements free of charge. Requests may be made by writing to:
Company Secretary
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
Our pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
183
projects in our pipeline
16
new molecular entities in our late-stage pipeline
2
new molecular entities under review
Contact us
Investor enquiries
Main Contacts
Christer Gruvris
BioPharmaceuticals (Cardiovascular, Renal and Metabolism), Finance & Fixed Income
-
Annual reports
Our Annual Report provides a wide range of information about our global business.
-
Our Pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development
